

LIGAND PHARMACEUTICALS INC  
Form SC 13G/A  
February 11, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. 2)\***

LIGAND PHARMACEUTICALS INC  
(Name of Issuer)  
Common Stock  
(Title of Class of Securities)  
53220K207  
(CUSIP Number)  
December 31, 2009  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 53220K207

NAMES OF REPORTING PERSONS

- 1** UBS AG (for the benefit and on behalf of UBS Investment Bank, Wealth Management USA, and Global Wealth Management and Business Banking business groups of UBS AG (See Item 7))

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

- 2**  
(a)   
(b)

SEC USE ONLY

**3**

CITIZENSHIP OR PLACE OF ORGANIZATION

- 4**  
Switzerland

SOLE VOTING POWER

**5**

NUMBER OF 5,770,524

SHARED VOTING POWER

**6**

SHARES BENEFICIALLY OWNED BY 0

SOLE DISPOSITIVE POWER

**7**

EACH REPORTING PERSON 5,770,524

SHARED DISPOSITIVE POWER

**8**

WITH: 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**9**

5,770,524

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.11%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

BK

---

CUSIP No. 53220K207

Item 1(a) Name of Issuer

LIGAND PHARMACEUTICALS INC

Item 1(b) Address of Issuer's Principal Executive Offices:

10275 Science Center Drive

San Diego, California 92121-1117

Item 2(a) Name of Person Filing:

UBS AG

Item 2(b) Address of Principal Business Office:

UBS AG's principal business office is:

Bahnhofstrasse 45

PO Box CH-8021

Zurich, Switzerland

Item 2(c) Citizenship:

Switzerland

Item 2(d) Title of Class of Securities

Common Stock

Item 2(e) CUSIP Number:

53220K207

Item 3. Type of Person Filing:

UBS AG is classified as a Bank as defined in section 3(a)(6) of the Act pursuant to no-action relief granted by the staff of the Securities and Exchange Commission.

---

CUSIP No. 53220K207

Item 4 (a)-(c)(iv). Ownership:

Items 5-11 of the cover pages are incorporated by reference.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on By the Parent Holding Company:

This statement on Schedule 13G is being filed by UBS AG on behalf of itself and the subsidiaries listed below. The securities being reported on by UBS AG were acquired directly by UBS AG directly and certain of such subsidiaries.

UBS AG London Branch

UBS Portfolio LLC

UBS Ltd

UBS Warburg Private Clients Ltd

UBS AG Tokyo Branch

UBS AG (Switzerland)

UBS Warburg Securities (Pty) Ltd (South Africa)

UBS International Ltd

UBS Warburg Securities Ltd

UBS Warburg Corretora de Cambio e Valores

Mobiliarios S.A.

UBS Warburg Trading S.A.

UBS Bank S.A.

UBS Bunting Warburg Inc

UBS Capital LLC

UBS AG Brazil

UBS Limited

UBS Capital Asia Pacific Ltd

CUSIP No. 53220K207  
UBS Capital Holdings LLC  
UBS Capital Jersey Ltd  
UBS Capital BV  
UBS Warburg AG (Frankfurt)  
UBS Securities Australia Ltd  
UBS Securities Canada Inc.  
UBS Securities Hong Kong Ltd  
UBS Securities (Japan) Ltd  
UBS Securities LLC  
UBS Securities New Zealand Limited  
UBS New Zealand Limited  
UBS AG Australia Branch  
UBS Capital Markets LP  
UBS Capital Latin America LDC  
UBS Securities France SA  
UBS AG Canada Branch  
PaineWebber Capital Inc  
Paine Webber International Inc  
UBS Financial Services Incorporated of Puerto Rico  
UBS Americas Inc  
UBS Financial Services Inc.  
UBS (Bahamas) LTD  
UBS (Cayman Islands) LTD  
UBS (France) SA  
UBS (Italia) SpA  
UBS (Luxemberg) SA  
UBS (Luxemberg) SA Austria Branch  
UBS (Monaco) S.A.  
UBS AG Brazil  
UBS AG New York (101 Park Avenue)  
UBS AG Hong Kong Branch  
UBS AG Jersey Branch  
UBS AG Singapore Branch  
UBS AG Stamford Branch  
UBS Assesores LTD  
UBS Bank (Canada)  
UBS Belgium SA/NV  
UBS Deutschland AG  
UBS Espana S.A.  
UBS Swiss Financial Advisors AG  
UBS Wealth Management AG  
UBS Wealth Management (UK) Ltd  
Item 8. Identification and Classification of Members of the Group  
Not Applicable  
Item 9 Notice of Dissolution of Group:  
Not Applicable  
Item 10. Certification:

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

By signing below, the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

CUSIP No. 53220K207

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

By: /s/ Anthony Defilippis  
Anthony Defilippis  
Executive Director

By: /s/ Gordon Kiesling  
Gordon Kiesling  
Executive Director

Date: February 11, 2010